Press Release

View printer-friendly version << Back
Juniper Pharmaceuticals to Host Investor Day on November 11, 2015

BOSTON, Oct. 27, 2015 /PRNewswire/ -- Juniper Pharmaceuticals, Inc., (Nasdaq: JNP) ("Juniper" or the "Company") announced today it will hold its 2015 Investor Day from 10:00 a.m. to 12:00 p.m. EST on Wednesday, November 11, 2015.

The Investor Day will be held at the Union League Club in New York City and hosted by members of Juniper's senior management team, with additional presentations by members of its Scientific Advisory Board. Juniper will provide insight into its pipeline, including COL-1077 10% lidocaine bioadhesive gel and key development programs utilizing its novel, segmented intravaginal ring (IVR) technology.

In-person attendance at the Juniper Investor Day is by invitation only, and an RSVP is required. A live webcast of the Investor Day will be available on Juniper's website under Presentations and through the following link:

A replay of the Investor Day webcast will be available approximately two hours following completion of the event at the aforementioned URLs. The archived webcast will be available for 90 days.

About Juniper Pharmaceuticals

Juniper Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing therapeutics that address unmet medical needs in women's health.  Juniper has a commercial product,  CRINONE® 8% (progesterone gel), which is marketed by Allergan, Inc. in the U.S. and by Merck KGaA, Darmstadt, Germany, in over 90 countries worldwide. The Company is advancing a pipeline of proprietary drug candidates leveraging novel delivery technologies.  Please visit for more information.

Juniper Pharmaceuticals™ is a trademark of Juniper Pharmaceuticals, Inc., in the U.S. and EU.

CRINONE® is a registered trademark of Allergan, Inc. in the U.S. and of Merck KGaA, Darmstadt, Germany, outside the U.S.

Forward Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This communication contains forward-looking statements, which statements are usually indicated by the words "may," "will," "plans," "believes," "expects," "anticipates," "potential," "should," or similar expressions, and which are generally not historical in nature. These include all statements relating to the anticipated disclosures at Juniper's R&D Day.  Management believes that these forward-looking statements are reasonable as and when made.  However, such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those projected in the forward-looking statements.  Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. These statements are based on management's current expectations and Juniper Pharmaceuticals does not undertake any responsibility to revise or update any forward-looking statements contained herein, except as expressly required by law.  For a discussion of certain risks and uncertainties associated with Juniper Pharmaceuticals' forward-looking statements, please review the Company's reports filed with the SEC, including, but not limited to, its Annual Report on Form 10-K for the period ended December 31, 2014.  

Amy Raskopf
Director, Corporate Communications
Juniper Pharmaceuticals
(917) 673-5775 

- or -

Lisa Wilson
President, In-Site Communications
(917) 543-9932 
Follow us on LinkedIn

Logo -

To view the original version on PR Newswire, visit:

SOURCE Juniper Pharmaceuticals, Inc.